{
    "clinical_study": {
        "@rank": "83895", 
        "arm_group": [
            {
                "arm_group_label": "Panel A-Healthy", 
                "arm_group_type": "Experimental", 
                "description": "Within each of the 5 rising dose treatment periods, 6 participants will be randomly assigned to receive a single oral dose of MK-8892, and 2 will be randomly assigned to receive a single oral dose of matching placebo according to a computer-generated allocation schedule. Dosing periods will alternate with Panel B."
            }, 
            {
                "arm_group_label": "Panel B-Healthy", 
                "arm_group_type": "Experimental", 
                "description": "Within each of the 4 rising dose treatment periods, 6 participants will be randomly assigned to receive a single oral dose of MK-8892, and 2 will be randomly assigned to receive a single oral dose of matching placebo according to a computer-generated allocation schedule. Dosing periods will alternate with Panel A."
            }, 
            {
                "arm_group_label": "Panel C-Mild/Moderate Hypertension", 
                "arm_group_type": "Experimental", 
                "description": "Within each of the 5 rising dose treatment periods, 6 participants will be randomly assigned to receive a single oral dose of MK-8892, and 2 will be randomly assigned to receive a single oral dose of matching placebo according to a computer-generated allocation schedule. Dosages will be determined by the results of Panels A and B."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate safety, tolerability and effects on central diastolic blood\n      pressure  (cDBP) of  MK-8892 given as single oral doses in healthy male participants (Panel\n      A and B) and in male participants with mild-to-moderate hypertension (Panel C)."
        }, 
        "brief_title": "A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Pulmonary Arterial Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension, Pulmonary", 
                "Hypertension"
            ]
        }, 
        "detailed_description": {
            "textblock": "Up to three planned panels of either 8 healthy participants (Panels A and B) or 8\n      participants with mild to moderate hypertension (Panel C) will be enrolled. In Panels A and\n      B, 8 participants will alternately receive single rising doses of MK-8892 or placebo. All\n      doses will be administered in the fasted state, except Panel A, Period 5 in which a standard\n      high-fat breakfast provided approximately 30 minutes prior to dosing.\n\n      Panel A will begin first. At least 3 days will elapse before participants in the alternate\n      panel (Panel B) will receive the next higher dose. In Panel C, 8 mild to moderate\n      hypertensive male participants will receive single rising doses of MK-8892 or placebo. Panel\n      C may begin after the first 4 periods of Panels A and B have completed dosing. For all\n      panels, there will be at least 7 days washout between treatment periods for any given\n      participant. Participants may only be enrolled in one panel of the study. Subsequent doses\n      in any panel will be administered only after careful evaluation of safety, tolerability, and\n      pharmacodynamic effects of a given dose."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Systolic blood pressure (SBP) > 110 and \u2264 140 mmHg for Panels A and  B, SBP values of\n             140-175 mmHg and diastolic blood pressure (DBP) of 90-105 mmHg on at least three\n             different occasions at the prestudy (screening) visit for Panel C. Participants being\n             treated with medication for their hypertension may be included as long as they are\n             titrated off of their medication\n\n          -  Body Mass Index (BMI) \u2265 18 kg/m^2 and \u2264 32 kg/m^2\n\n          -  Healthy (with the exception of hypertensive subjects in Panel C)\n\n          -  No clinically significant abnormality on electrocardiogram (ECG)\n\n          -  No history of clinically significant cardiac disease\n\n          -  No history of heart failure\n\n          -  Nonsmoker and/or has not used nicotine or nicotine-containing products for at least 6\n             months\n\n        Exclusion Criteria:\n\n          -  Mentally or legally incapacitated\n\n          -  History of stroke, chronic seizures, or major neurological disorder\n\n          -  History of clinically significant endocrine, gastrointestinal, cardiovascular (except\n             mild to moderate hypertension), hematological, hepatic, immunological, renal,\n             respiratory, or genitourinary abnormalities or diseases\n\n          -  Functional disability that can interfere  with rising from a sitting position to the\n             standing position\n\n          -  History of cancer (malignancy)\n\n          -  History of significant multiple and/or severe allergies (e.g. food, drug, latex\n             allergy), or has had an anaphylactic reaction or significant intolerability to\n             prescription or nonprescription drugs or food\n\n          -  Positive for hepatitis B, hepatitis C, or Human Immunodeficiency Virus (HIV)\n\n          -  Has had major surgery, donated or lost 1 unit of blood or participated in another\n             investigational study within 4 weeks\n\n          -  Has participated in another investigational trial within 4 weeks\n\n          -  Unable to refrain from or anticipates the use of any medication during the study\n\n          -  Anticipates using medication for erectile dysfunction during the study\n\n          -  Uses or anticipates using organic nitrates during the study (e.g. nitroglycerin,\n             isosorbide mononitrate, isosorbide dinitrate, pentaerythritol)\n\n          -  Anticipates using cytochrome P450 inhibitors (e.g. ketoconazole) or inducers (e.g.\n             rifampin) during the study\n\n          -  Consumes excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic\n             beverages per day\n\n          -  Consumes excessive amounts, defined as greater than 6 servings of coffee, tea, cola,\n             or other caffeinated beverages per day\n\n          -  Regular user (including recreational user) of illicit drugs or has a history of drug\n             (including alcohol) abuse within approximately 1 year"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01798849", 
            "org_study_id": "8892-001", 
            "secondary_id": "2012-005472-34"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Panel A-Healthy", 
                    "Panel B-Healthy", 
                    "Panel C-Mild/Moderate Hypertension"
                ], 
                "intervention_name": "MK-8892", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Panel A-Healthy", 
                    "Panel B-Healthy", 
                    "Panel C-Mild/Moderate Hypertension"
                ], 
                "intervention_name": "Placebo for MK-8892", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 29, 2013", 
        "number_of_arms": "3", 
        "official_title": "A Single Rising Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8892", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of Participants who Report 1 or more Adverse Event (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 7 weeks"
            }, 
            {
                "measure": "Number of Participants who Discontinued from the Study due to an AE", 
                "safety_issue": "Yes", 
                "time_frame": "up to 7 weeks"
            }, 
            {
                "measure": "24-hour Time-weighted Average (TWA0-24hr) for Central Diastolic Blood Pressure  (cDBP)", 
                "safety_issue": "No", 
                "time_frame": "Predose to 24 hours Postdose (for each Dosing Period of Each Panel)"
            }
        ], 
        "removed_countries": {
            "country": "Belgium"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01798849"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "TWA0-24hrs for Peripheral Diastolic Blood Pressure (pDBP)", 
                "safety_issue": "No", 
                "time_frame": "Predose to 24 hours Postdose (for each Dosing Period of Each Panel)"
            }, 
            {
                "measure": "TWA0-24hrs for Heart Rate (HR)", 
                "safety_issue": "No", 
                "time_frame": "Predose to 24 hours Postdose (for each Dosing Period of Each Panel)"
            }, 
            {
                "measure": "TWA0-24hr for Augmentation Index (AIx)", 
                "safety_issue": "No", 
                "time_frame": "Predose to 24 hours Postdose (for each Dosing Period of Each Panel)"
            }, 
            {
                "measure": "Area Under the Concentration Time-curve from Hour 0 to 24 hours (AUC0-24hr) of MK-8892", 
                "safety_issue": "No", 
                "time_frame": "predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose"
            }, 
            {
                "measure": "Area Under the Concentration-time Curve from Time zero to the Time of the Last  Measurable Plasma Concentration Time Point (AUC0-last) of MK-8892", 
                "safety_issue": "No", 
                "time_frame": "predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose"
            }, 
            {
                "measure": "Area Under the Concentration Time-curve from Hour 0 to infinity (AUC0-inf) of MK-8892", 
                "safety_issue": "No", 
                "time_frame": "predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose"
            }, 
            {
                "measure": "Maximum concentration (Cmax) of MK-8892", 
                "safety_issue": "No", 
                "time_frame": "predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose"
            }, 
            {
                "measure": "Time to Cmax (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose"
            }, 
            {
                "measure": "Apparent Terminal Half-life (t1/2) of MK-8892", 
                "safety_issue": "No", 
                "time_frame": "predose and 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 48, 72, and 96 hours postdose"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}